Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 10:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 622 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hepatic Cirrhosis Clear all
Completed Phase 3 Interventional

Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin

NCT00039962
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic
Interventions
thymalfasin (thymosin alpha 1), PEGinterferon alfa-2a
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
54
States / cities
Mobile, Alabama • Scottsdale, Arizona • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

NCT03067129
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation
Drug
Lead sponsor
AbbVie
Industry
Eligibility
3 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
15
States / cities
San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 22, 2026, 10:05 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

NCT04048876
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Liver Cirrhosis
Interventions
CC-90001, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
64
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 3 Interventional Results available

BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis

NCT00736840
View directory record Official record
Conditions
Chronic Liver Disease
Interventions
c13 methacetin solution with breath analyzer
Device
Lead sponsor
Meridian Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Los Angeles, California • Detroit, Michigan • Cleveland, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 1 Interventional

A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT05395481
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Interventions
LY3849891, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
13
States / cities
Chandler, Arizona • Orange, California • Rialto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 22, 2026, 10:05 PM EDT
Withdrawn Phase 3 Interventional

Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE

NCT00787436
View directory record Official record
Conditions
Gastrointestinal Hemorrhage, Portal Hypertension
Interventions
Thalidomide
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis

NCT02994056
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Tampa, Florida • Chicago, Illinois • Catonsville, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 22, 2026, 10:05 PM EDT
Completed No phase listed Observational

FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)

NCT02922751
View directory record Official record
Conditions
Biliary Atresia, Alagille Syndrome, Alpha1 Anti-Trypsin Deficiency, Portal Hypertension, Liver Fibrosis, Cholestasis
Interventions
Liver Stiffness Measurement (LSM)
Other
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
Up to 21 Years
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis

NCT04604652
View directory record Official record
Conditions
Primary Biliary Cholangitis, Primary Biliary Cirrhosis, Cholangitis, Cholestasis, Biliary Tract Diseases, Bile Duct Stricture
Interventions
HTD1801 (BUDCA)
Drug
Lead sponsor
HighTide Therapeutics (Hong Kong) Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
12
States / cities
Miami, Florida • Atlanta, Georgia • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 22, 2026, 10:05 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis

NCT02943447
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Cilofexor, Placebo to match cilofexor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
13
States / cities
Sacramento, California • Aurora, Colorado • Lakewood Rch, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Sep 22, 2026, 10:05 PM EDT
Recruiting Phase 1 Interventional

Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics

NCT05490888
View directory record Official record
Conditions
Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic
Interventions
PHIN-214 Subcutaneous injection
Drug
Lead sponsor
PharmaIN
Industry
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Chandler, Arizona • Coronado, California • Marrero, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 1 Interventional Results available

Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation

NCT01147380
View directory record Official record
Conditions
Liver Cirrhosis, Hepatocellular Carcinoma, Evidence of Liver Transplantation
Interventions
Liver NK cell inoculation
Biological
Lead sponsor
Seigo Nishida
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Sep 22, 2026, 10:05 PM EDT
Terminated Phase 4 Interventional

Quality of Life and Nutritional Improvements in Cirrhotic Patients

NCT01842113
View directory record Official record
Conditions
Liver Cirrhosis, Hepatic Encephalopathy, Portal Hypertension
Interventions
Rifaximin, Lactulose, Lactulose Placebo, Rifaximin Placebo
Drug
Lead sponsor
Tampa General Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2013 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Not applicable Interventional Results available

Health IT Generated PROs to Improve Outcomes in Cirrhosis

NCT03564626
View directory record Official record
Conditions
Cirrhosis
Interventions
Health-IT +/- Scheduled Follow Up
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Rochester, Minnesota • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Sonic Incytes Liver Incytes System, Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF

NCT04682600
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Liver Fibroses, Liver Steatoses
Interventions
Liver Incytes System
Device
Lead sponsor
Sonic Incytes
Industry
Eligibility
19 Years to 75 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 22, 2026, 10:05 PM EDT
Active, not recruiting Phase 4 Interventional

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

NCT05044819
View directory record Official record
Conditions
Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex
Interventions
Cannabidiol
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
26
States / cities
Little Rock, Arkansas • Downey, California • Long Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 22, 2026, 10:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Acoustic Liver Biopsy in Normals and in Patients With Cirrhosis Using Endoscopic Ultrasound

NCT01208311
View directory record Official record
Conditions
Alcoholism, Cirrhosis, Hepatitis c
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
20 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2016
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.

NCT03226067
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
GKT137831, Placebo oral capsule
Drug
Lead sponsor
Calliditas Therapeutics AB
Industry
Eligibility
18 Years to 80 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Phoenix, Arizona • Sacramento, California • Ventura, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Not applicable Interventional

Clinical Food Study to Evaluate the Effect of KB174 on the Gut Microbiome in Subjects With Well-compensated Cirrhosis

NCT03855956
View directory record Official record
Conditions
Early Cirrhosis
Interventions
KB174, Maltodextrin
Other
Lead sponsor
Kaleido Biosciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
4
States / cities
Hollywood, Florida • Miami, Florida • Winter Park, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Sep 22, 2026, 10:05 PM EDT
Completed No phase listed Observational Results available

Patient Buddy App for the Prevention of Avoidable Readmission in Cirrhosis

NCT02534805
View directory record Official record
Conditions
Cirrhosis
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 1 Interventional

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

NCT02143401
View directory record Official record
Conditions
Cirrhosis, Hepatitis B Infection, Hepatitis C Infection, Metastatic Malignant Solid Neoplasm, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Refractory Malignant Neoplasm, Stage IV Hepatocellular Carcinoma AJCC v7, Unresectable Solid Neoplasm
Interventions
Laboratory Biomarker Analysis, Navitoclax, Pharmacological Study, Sorafenib, Sorafenib Tosylate
Other · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
10
States / cities
Scottsdale, Arizona • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 22, 2026, 10:05 PM EDT
Recruiting Not applicable Interventional

Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

NCT06425380
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis
Interventions
Resistant Potato Starch
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Not applicable Interventional

Efficacy and Safety Study on Nasogastric (NG) Tube in Patients With Upper Gastrointestinal Bleed

NCT00689754
View directory record Official record
Conditions
Gastrointestinal Hemorrhage, Liver Cirrhosis
Interventions
nasogastric tube placement
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 2Phase 3 Interventional

Communication During Hospitalization About Resuscitation Trial

NCT02984124
View directory record Official record
Conditions
Severe Life-limiting COPD, Severe Life-limiting Heart Failure, Severe Life-limiting Cirrhosis, Severe Life-limiting Malignancy, Severe Functional Impairment, End Stage Renal Disease
Interventions
Informed Assent Discussion, Usual Care with Attention Control
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
65 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
4
States / cities
Chapel Hill, North Carolina • Charleston, South Carolina • Burlington, Vermont + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 22, 2026, 10:05 PM EDT